SEC Tracker
Get the app
CTXR · XBRL financial data

Citius Pharmaceuticals financial statements, every quarter

The same tables from 12 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

Download Excel Download CSV
How these numbers work
  • Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
  • Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
  • * marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
  • 0 means a filing states zero; a dash (—) means no filing states that number.
  • “year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
  • Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
  • Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
  • Shares outstanding come from each filing's cover page, as of the date printed there.
  • Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

CSV

Fiscal quarters (CTXR's year ends in late September)

In thousands of dollarsSep 30, 2023Dec 31, 2023Mar 31, 2024Jun 30, 2024†Sep 30, 2024Dec 31, 2024Mar 31, 2025Jun 30, 2025Sep 30, 2025Dec 31, 2025Mar 31, 2026Jun 30, 2026
Revenue—————————3,9441,6671,494
Cost of revenue—————————789329492
Gross profit—————————3,1551,3381,002
Research and development2,883*2,6223,6062,7642,915*2,1273,7671,6211,642*1,6001,6341,054
General and administrative4,166*3,6614,2864,8095,494*5,3884,7924,4473,906*5,72126,3916,149
Total operating expenses10,125*9,34110,97010,63411,050*10,04011,2618,7888,437*12,17433,53312,734
Operating income (loss)(10,125)*(9,341)(10,970)(10,634)(11,050)*(10,040)(11,261)(8,788)(8,437)*(9,019)(32,195)(11,732)
Interest income325*254182205117*23132153*4554117
Interest expense———————17296*15633198
Income tax expense (benefit)144*144144144144*264264264264*264(231)(107)
Net income (loss)(9,944)*(9,231)(8,544)(10,573)—(10,281)(11,512)—————
Earnings per share, basic USD per share—(1.45)(1.34)(1.57)—(1.30)(1.27)(0.80)—(0.38)(0.95)(0.34)
Earnings per share, diluted USD per share—(1.45)(1.34)(1.57)—(1.30)(1.27)(0.80)—(0.38)(0.95)(0.34)
Weighted average shares, basic thousands of shares158,858*158,956159,072173,857—7,4928,58111,007—21,49522,37626,170
Weighted average shares, diluted thousands of shares158,858*158,956159,072173,857—7,4928,58111,007—21,49522,37626,170
  • † Share count changed about 1/23 in the period ending 2024-09-30, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.

Balance sheet

CSV

Fiscal quarters (CTXR's year ends in late September)

In thousands of dollarsSep 30, 2023Dec 31, 2023Mar 31, 2024Jun 30, 2024†Sep 30, 2024Dec 31, 2024Mar 31, 2025Jun 30, 2025Sep 30, 2025Dec 31, 2025Mar 31, 2026Jun 30, 2026
Cash and cash equivalents26,48120,34612,56017,9113,2521,100266,0894,2527,7214,59017,008
Accounts receivable—————————4,0491,079686
Inventory————8,26914,38115,33917,20922,28722,63922,66022,626
Total current assets34,37028,21021,57428,00614,22118,32718,37424,61127,93437,94531,68643,331
Property and equipment, net110—————————
Right-of-use asset454404353300246191922881819835795753
Goodwill9,3479,3479,3479,3479,3479,3479,3479,3479,3479,3479,3479,347
Total assets103,61197,40090,71197,091116,652120,703121,481127,677130,938140,392132,541142,255
Accounts payable2,9272,6472,6701,6634,9277,3649,36810,09413,69411,0219,4548,038
Accrued liabilities476277151550176,2428,7798,5244,1904,69324,13825,914
Commercial paper—————300,000300,000300,000300,000300,000300,000300,000
Total current liabilities5,7795,5794,1744,15235,81544,80649,87751,84244,91538,20755,01651,649
Lease liability, non-current2632051458421—787767725682637591
Total liabilities12,18012,06510,74410,80642,55051,78457,90660,11653,41046,92463,45666,347
Accumulated deficit(162,231)(171,463)(180,007)(190,580)(201,370)(211,138)(222,055)(230,845)(238,804)(247,025)(268,256)(277,119)
Total stockholders' equity90,83184,73479,36785,68470,07765,40860,65965,05967,55079,95861,54266,613
Total liabilities and equity103,61197,40090,71197,091116,652120,703121,481127,677130,938140,392132,541142,255
Common shares outstanding (cover page) thousands of shares158,967159,095180,673180,7257,7278,59310,29017,01220,76322,37627,45327,453
  • † Share count changed about 1/23 in the period ending 2024-09-30, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.

Cash flows

CSV

Fiscal quarters (CTXR's year ends in late September)

In thousands of dollarsSep 30, 2023Dec 31, 2023Mar 31, 2024Jun 30, 2024†Sep 30, 2024Dec 31, 2024Mar 31, 2025Jun 30, 2025Sep 30, 2025Dec 31, 2025Mar 31, 2026Jun 30, 2026
Net income (loss)(9,944)*(9,231)(8,544)(10,573)—(10,281)(11,512)—————
Stock-based compensation3,076*3,0583,0783,0622,641*2,5252,7022,7202,890*4,2803,7883,811
Net cash from operating activities(6,800)*(6,135)(7,786)*(8,367)*(5,913)*(4,726)(4,539)*(5,407)*(11,881)*(13,009)(1,300)*(8,678)*
Net cash from investing activities————year only———year only(4,400)(600)*(2,000)*
Proceeds from issuing common stock————(13,467)*2,5743,466*10,469*15,794*20,878(63)*4,453*
Net cash from financing activities(1)*———(3,747)*2,5743,466*11,469*15,794*20,878(1,231)*23,095*
  • † Share count changed about 1/23 in the period ending 2024-09-30, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.

Compare with peers

SIC 2834 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen
  • SIC 2834 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
  • Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
  • Runway shows only for companies burning cash with under $10B of public float.
  • * marks a quarter worked out from the filing totals: for a 10-Q, the year-to-date total less the earlier one.
  • A cell reading “not reported” means the filings give no figure for that quarter alone.
CompanyCash ($K)Revenue, quarter ($K)Operating cash flow, quarter ($K)Shares outstandingRunwayQuarter
Citius Pharmaceuticals17,0081,494(8,678)*27.5M2.0 quarters 10-QJun 30, 2026
Phio Pharmaceuticals12,996not reported(4,035)*11.6M3.2 quarters 10-QJun 30, 2026
Palisade Bio125,172500(7,603)*174.3M16.5 quarters 10-QJun 30, 2026
Cocrystal Pharma2,169105(2,516)*19.3M0.9 quarters 10-QJun 30, 2026
Cypherpunk Technologies7,624not reported(2,692)*107.8M2.8 quarters 10-QJun 30, 2026
Brainstorm Cell Therapeutics22not reported(895)11.0M0.0 quarters 10-QJun 30, 2026
Kiora Pharmaceuticals7,077not reported(1,892)*4.4M8.9 quarters 10-QJun 30, 2026
Scienture Holdings8,188344(3,132)*41.1M2.6 quarters 10-QJun 30, 2026
Cellectar Biosciences33,994not reported(6,010)*9.5M5.7 quarters 10-QJun 30, 2026

Not investment advice. Not affiliated with the U.S. SEC.